EMEA-001371-PIP01-12

Key facts

Active substance
Clazakizumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0029/2014
PIP number
EMEA-001371-PIP01-12
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of chronic idiopathic arthritis (including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylarthritis and juvenile idiopathic arthritis)
Route(s) of administration
Subcutaneous use
Contact for public enquiries
CSL Behring GmbH

Tel. +49 151 44162443
E-mail: PIP.CSLBehring@cslbehring.com

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating